Leerink Partners Upgrades Replimune Group to Outperform, Raises Price Target to $17
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsUpgradesPrice Target
Leerink Partners analyst Jonathan Chang upgrades Replimune Group (NASDAQ:REPL) from Market Perform to Outperform and raises the price target from $11 to $17.
Leerink Partners analyst Jonathan Chang upgrades Replimune Group (NASDAQ:REPL) from Market Perform to Outperform and raises the price target from $11 to $17.